Adrenacklick

Mylan NV (NASDAQ: MYL) faced its fair share of controversy earlier this year for increasing the price of its potentially life-saving EpiPen product by more than 400 percent over the past few years. On Friday, Mylan announced the launch of the authorized generic for EpiPen at a wholesale acquisition...